Загрузка...
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
AIMS: Heart failure (HF) is a common co‐morbidity in non‐valvular atrial fibrillation (NVAF) patients and a potent risk factor for stroke, bleeding, and a decreased time‐in‐therapeutic range with warfarin. We assessed the real‐world effectiveness and safety of rivaroxaban and warfarin in NVAF patien...
Сохранить в:
| Опубликовано в: : | ESC Heart Fail |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6352884/ https://ncbi.nlm.nih.gov/pubmed/30299591 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12365 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|